Drug-Drug Interaction Study in Healthy Subjects

Completed · Phase 1

Conditions studied: Hepatitis C

In brief

The purpose of this study is to assess the pharmacokinetics and safety of BMS-790052 and BMS-650032 when co-administered and when administered alone

Key facts

Study ID

NCT00904059

Run by

Bristol-Myers Squibb

People needed

28

Starts

2009-05-01

Expected to finish

2009-07-01

Last updated by the study team

2011-01-07

Who can join

Age: 18 and older, up to 49. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male and female subjects aged 18 to 49 years
• Females who are not of childbearing potential, pregnant or breastfeeding
• Subject Body Mass Index (BMI) of 18 to 32 kg/m²

You may not qualify if…

• Women of child bearing potential
• Male subjects who have sex with women who are unwilling to agree to practice male barrier contraception during study participation and for a least 12 weeks following dosing
• Any significant acute or chronic medical illness
• Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations
• Prior exposure to BMS-650032 or BMS-790052
• Positive for HIV or HCV

Where it is running

• Ppd Development, Lp — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.